|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NUDT21 |
Gene summary for NUDT21 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NUDT21 | Gene ID | 11051 |
| Gene name | nudix hydrolase 21 | |
| Gene Alias | CFIM25 | |
| Cytomap | 16q13 | |
| Gene Type | protein-coding | GO ID | GO:0002244 | UniProtAcc | A0A024R6W2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11051 | NUDT21 | LZE2T | Human | Esophagus | ESCC | 2.51e-02 | 9.56e-01 | 0.082 |
| 11051 | NUDT21 | LZE3D | Human | Esophagus | HGIN | 3.06e-04 | 6.11e-01 | 0.0668 |
| 11051 | NUDT21 | LZE4T | Human | Esophagus | ESCC | 4.51e-31 | 9.90e-01 | 0.0811 |
| 11051 | NUDT21 | LZE7T | Human | Esophagus | ESCC | 4.15e-09 | 7.53e-01 | 0.0667 |
| 11051 | NUDT21 | LZE8T | Human | Esophagus | ESCC | 1.88e-05 | 5.88e-01 | 0.067 |
| 11051 | NUDT21 | LZE22D1 | Human | Esophagus | HGIN | 3.52e-04 | 8.93e-02 | 0.0595 |
| 11051 | NUDT21 | LZE24T | Human | Esophagus | ESCC | 3.43e-20 | 7.94e-01 | 0.0596 |
| 11051 | NUDT21 | LZE21T | Human | Esophagus | ESCC | 3.40e-06 | 4.38e-01 | 0.0655 |
| 11051 | NUDT21 | LZE6T | Human | Esophagus | ESCC | 7.73e-07 | 3.78e-01 | 0.0845 |
| 11051 | NUDT21 | P1T-E | Human | Esophagus | ESCC | 1.15e-05 | 6.49e-01 | 0.0875 |
| 11051 | NUDT21 | P2T-E | Human | Esophagus | ESCC | 3.00e-30 | 5.66e-01 | 0.1177 |
| 11051 | NUDT21 | P4T-E | Human | Esophagus | ESCC | 4.28e-51 | 1.68e+00 | 0.1323 |
| 11051 | NUDT21 | P5T-E | Human | Esophagus | ESCC | 3.13e-70 | 1.37e+00 | 0.1327 |
| 11051 | NUDT21 | P8T-E | Human | Esophagus | ESCC | 7.13e-39 | 8.11e-01 | 0.0889 |
| 11051 | NUDT21 | P9T-E | Human | Esophagus | ESCC | 1.73e-12 | 4.65e-01 | 0.1131 |
| 11051 | NUDT21 | P10T-E | Human | Esophagus | ESCC | 1.74e-34 | 5.33e-01 | 0.116 |
| 11051 | NUDT21 | P11T-E | Human | Esophagus | ESCC | 3.31e-13 | 8.22e-01 | 0.1426 |
| 11051 | NUDT21 | P12T-E | Human | Esophagus | ESCC | 2.60e-38 | 7.22e-01 | 0.1122 |
| 11051 | NUDT21 | P15T-E | Human | Esophagus | ESCC | 1.54e-53 | 1.25e+00 | 0.1149 |
| 11051 | NUDT21 | P16T-E | Human | Esophagus | ESCC | 5.00e-40 | 7.17e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006379 | Liver | HCC | mRNA cleavage | 17/7958 | 22/18723 | 9.84e-04 | 5.70e-03 | 17 |
| GO:0031442 | Liver | HCC | positive regulation of mRNA 3'-end processing | 10/7958 | 11/18723 | 1.30e-03 | 7.01e-03 | 10 |
| GO:0098789 | Liver | HCC | pre-mRNA cleavage required for polyadenylation | 11/7958 | 13/18723 | 2.38e-03 | 1.16e-02 | 11 |
| GO:0051262 | Liver | HCC | protein tetramerization | 50/7958 | 87/18723 | 3.42e-03 | 1.55e-02 | 50 |
| GO:0051290 | Liver | HCC | protein heterotetramerization | 12/7958 | 15/18723 | 3.56e-03 | 1.59e-02 | 12 |
| GO:0098787 | Liver | HCC | mRNA cleavage involved in mRNA processing | 11/7958 | 14/18723 | 6.81e-03 | 2.73e-02 | 11 |
| GO:0051291 | Liver | HCC | protein heterooligomerization | 17/7958 | 25/18723 | 8.94e-03 | 3.45e-02 | 17 |
| GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
| GO:190331118 | Oral cavity | OSCC | regulation of mRNA metabolic process | 197/7305 | 288/18723 | 2.83e-24 | 7.16e-22 | 197 |
| GO:005068417 | Oral cavity | OSCC | regulation of mRNA processing | 104/7305 | 137/18723 | 1.32e-18 | 1.58e-16 | 104 |
| GO:007182620 | Oral cavity | OSCC | ribonucleoprotein complex subunit organization | 152/7305 | 227/18723 | 1.05e-17 | 1.01e-15 | 152 |
| GO:002261820 | Oral cavity | OSCC | ribonucleoprotein complex assembly | 146/7305 | 220/18723 | 1.53e-16 | 1.23e-14 | 146 |
| GO:19033139 | Oral cavity | OSCC | positive regulation of mRNA metabolic process | 82/7305 | 118/18723 | 1.77e-11 | 6.13e-10 | 82 |
| GO:00311242 | Oral cavity | OSCC | mRNA 3'-end processing | 49/7305 | 62/18723 | 1.40e-10 | 4.14e-09 | 49 |
| GO:00905012 | Oral cavity | OSCC | RNA phosphodiester bond hydrolysis | 95/7305 | 152/18723 | 3.65e-09 | 8.22e-08 | 95 |
| GO:00311232 | Oral cavity | OSCC | RNA 3'-end processing | 75/7305 | 116/18723 | 1.93e-08 | 3.79e-07 | 75 |
| GO:00063782 | Oral cavity | OSCC | mRNA polyadenylation | 34/7305 | 44/18723 | 2.63e-07 | 4.10e-06 | 34 |
| GO:00903052 | Oral cavity | OSCC | nucleic acid phosphodiester bond hydrolysis | 142/7305 | 261/18723 | 2.90e-07 | 4.43e-06 | 142 |
| GO:00314403 | Oral cavity | OSCC | regulation of mRNA 3'-end processing | 24/7305 | 28/18723 | 4.78e-07 | 7.04e-06 | 24 |
| GO:00436312 | Oral cavity | OSCC | RNA polyadenylation | 34/7305 | 45/18723 | 6.73e-07 | 9.53e-06 | 34 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa030159 | Esophagus | HGIN | mRNA surveillance pathway | 30/1383 | 97/8465 | 2.48e-04 | 2.69e-03 | 2.14e-03 | 30 |
| hsa0301514 | Esophagus | HGIN | mRNA surveillance pathway | 30/1383 | 97/8465 | 2.48e-04 | 2.69e-03 | 2.14e-03 | 30 |
| hsa0301524 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
| hsa0301534 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
| hsa030154 | Liver | Cirrhotic | mRNA surveillance pathway | 46/2530 | 97/8465 | 1.92e-04 | 1.30e-03 | 8.03e-04 | 46 |
| hsa0301511 | Liver | Cirrhotic | mRNA surveillance pathway | 46/2530 | 97/8465 | 1.92e-04 | 1.30e-03 | 8.03e-04 | 46 |
| hsa0301521 | Liver | HCC | mRNA surveillance pathway | 66/4020 | 97/8465 | 3.16e-05 | 1.88e-04 | 1.04e-04 | 66 |
| hsa0301531 | Liver | HCC | mRNA surveillance pathway | 66/4020 | 97/8465 | 3.16e-05 | 1.88e-04 | 1.04e-04 | 66 |
| hsa030158 | Oral cavity | OSCC | mRNA surveillance pathway | 75/3704 | 97/8465 | 1.30e-11 | 2.01e-10 | 1.02e-10 | 75 |
| hsa0301513 | Oral cavity | OSCC | mRNA surveillance pathway | 75/3704 | 97/8465 | 1.30e-11 | 2.01e-10 | 1.02e-10 | 75 |
| hsa0301523 | Oral cavity | LP | mRNA surveillance pathway | 50/2418 | 97/8465 | 1.39e-06 | 1.50e-05 | 9.66e-06 | 50 |
| hsa0301533 | Oral cavity | LP | mRNA surveillance pathway | 50/2418 | 97/8465 | 1.39e-06 | 1.50e-05 | 9.66e-06 | 50 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NUDT21 | SNV | Missense_Mutation | c.311N>G | p.Phe104Cys | p.F104C | O43809 | protein_coding | tolerated(0.07) | probably_damaging(0.997) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
| NUDT21 | SNV | Missense_Mutation | c.197N>A | p.Arg66His | p.R66H | O43809 | protein_coding | tolerated(0.07) | benign(0.08) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| NUDT21 | SNV | Missense_Mutation | novel | c.361N>A | p.Leu121Ile | p.L121I | O43809 | protein_coding | deleterious(0.04) | possibly_damaging(0.807) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| NUDT21 | SNV | Missense_Mutation | novel | c.338N>T | p.Pro113Leu | p.P113L | O43809 | protein_coding | deleterious(0.03) | benign(0.009) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| NUDT21 | SNV | Missense_Mutation | novel | c.368N>A | p.Arg123His | p.R123H | O43809 | protein_coding | tolerated(0.05) | benign(0.123) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NUDT21 | SNV | Missense_Mutation | novel | c.210A>T | p.Glu70Asp | p.E70D | O43809 | protein_coding | tolerated(0.22) | benign(0.098) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NUDT21 | SNV | Missense_Mutation | novel | c.203N>C | p.Arg68Thr | p.R68T | O43809 | protein_coding | deleterious(0) | possibly_damaging(0.456) | TCGA-CN-4739-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
| NUDT21 | SNV | Missense_Mutation | novel | c.214N>C | p.Asp72His | p.D72H | O43809 | protein_coding | deleterious(0.01) | benign(0.073) | TCGA-CN-A642-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| NUDT21 | SNV | Missense_Mutation | novel | c.195N>T | p.Gln65His | p.Q65H | O43809 | protein_coding | deleterious(0.01) | possibly_damaging(0.75) | TCGA-D7-6822-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |